Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Read also

Ventus and Genentech

Ventus and Genentech partner for small-molecule medicine discovery

Aspire Pharma’s

Acquisition strengthens Aspire Pharma’s strategic portfolio

Alkermes to acquire Avadel for $2.1bn

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.

NanoViricides

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies